The Top 5 Biosimilars Articles for the Week of February 24

February 29, 2020

The Center for Biosimilars® recaps the top stories for the week of February 24, 2020.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 24, 2020.

Number 5: A new review analyzing the risk of cancer in patients with psoriasis found no increased risk for those treated with biologics.

Number 4: The FDA amends the definition of “biological product” in its final rule regarding the regulatory shift that begins March 23, when insulin and other biological products shift to a different approval pathway.

Number 3: A year-in-review article outlines 2019 studies about nonmedical switching and finds evidence to support moving from originator biologics to biosimilars in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

Number 2: AbbVie reports strong revenues for next-generation products the company hopes will provide fill-in revenue as Humira sales decline and more adalimumab biosimilars to the blockbuster arthritis drug enter international markets.

Number 1: The launch of Pfizer’s trastuzumab biosimilar, Trazimera, means the originator product Herceptin now has 3 biosimilar competitors.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Endocrinology | Policy | Regulatory | Business

x